Atara Biotherapeutics Announces Completion of the ATA188 Phase 2 EMBOLD Study Interim Analysis in Pa
 Independent Data and Safety Monitoring Committee Recommends Continuing Study Without Sample Size Adjustment  IDSMC Did Not Identify Any Safety ConcernsPhase 2 Study Target Enrollment Achieved; Final Data and Communication Expected in October 2023Conference Call and Webcast Today at 2:00 p.m. PDT/5:00 p.m. EDTSOUTH...
United States South San Francisco Eric Hyllengren Jakob Dupont Pascal Touchon Atara Biotherapeutics Inc
Source: pharmiweb.com